The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers
Open accessPublished version of a preprint
Abstract
BACKGROUND: The relationship between the presence of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the risk of subsequent reinfection remains unclear. METHODS: We investigated the incidence of SARS-CoV-2 infection confirmed by polymerase chain reaction (PCR) in seropositive and seronegative health care workers attending testing of asymptomatic and symptomatic staff at Oxford University Hospitals in the United Kingdom. Baseline antibody status was determined by anti-spike (primary analysis) and anti-nucleocapsid IgG assays, and staff members were followed for up to 31 weeks. We estimated the relative incidence of PCR-positive test results and new symptomatic infection according to antibody status, adjusting for age, participant-reported gender, and changes in incidence over time. RESULTS: A total of 12,541 health care workers participated and had anti-spike IgG measured; 11,364 were followed up after negative antibody results and 1265 after positive results, including 88 in whom seroconversion occurred during follow-up. A total of 223 anti-spike-seronegative health care workers had a positive PCR test (1.09 per 10,000 days at risk), 100 during screening while they were asymptomatic and 123 while symptomatic, whereas 2 anti-spike-seropositive health care workers had a positive PCR test (0.13 per 10,000 days at risk), and both workers were asymptomatic when tested (adjusted incidence rate ratio, 0.11; 95% confidence interval, 0.03 to 0.44; P = 0.002). There were no symptomatic infections in workers with anti-spike antibodies. Rate ratios were similar when the anti-nucleocapsid IgG assay was used alone or in combination with the anti-spike IgG assay to determine baseline status. CONCLUSIONS: The presence of anti-spike or anti-nucleocapsid IgG antibodies was associated with a substantially reduced risk of SARS-CoV-2 reinfection in the ensuing 6 months. (Funded by the U.K. Government Department of Health and Social Care and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This study estimated that seropositivity at enrolment reduced the incidence of detected reinfection by almost 89% over a median follow-up of 139 days.”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [53]
In the citing paper
“a level of protection that is not significantly different to the 89–95% protection that has been estimated following natural infection53,54.”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [53]
In the citing paper
“Preexisting immunity to SARS-CoV-2 is associated with protection against reinfection in humans (9–11) and in nonhuman primates (12, 13).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
To, K. K., Tsang, O. T.-Y., Leung, W.-S., Tam, A. R., Wu, T.-C., Lung, D. C., Yip, C. C., Cai, J., Chan, J. M., Chik, T. S., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30196-1 · Cited by 3,045
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J., Hu, J.-L., Xu, W., Zhang, Y., Lv, F.-J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0965-6 · Cited by 2,686
Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals
Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2456-9 · Cited by 1,853
Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J. A., Hemmings, O., O’Byrne, A., Kouphou, N., Galao, R. P., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00813-8 · Cited by 1,419
Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
Wajnberg, A., Amanat, F., Firpo, A., Altman, D. R., Bailey, M. J., Mansour, M., McMahon, M., Meade, P., Mendu, D. R., Muellers, K., et al. (2020) · Science · doi:10.1126/science.abd7728 · Cited by 1,195
Humoral Immune Response to SARS-CoV-2 in Iceland
Gudbjartsson, D. F., Norddahl, G. L., Melsted, P., Gunnarsdottir, K., Holm, H., Eythorsson, E., Arnthorsson, A. O., Helgason, D., Bjarnadottir, K., Ingvarsson, R. F., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2026116 · Cited by 903
Vaccines: Correlates of Vaccine‐Induced Immunity
Plotkin, S. A. (2008) · Clinical Infectious Diseases · doi:10.1086/589862 · Cited by 829
Genomic evidence for reinfection with SARS-CoV-2: a case study
Tillett, R. L., Sevinsky, J. R., Hartley, P. D., Kerwin, H., Crawford, N. F., Gorzalski, A. J., Laverdure, C., Verma, S. C., Rossetto, C. C., Jackson, D. K., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30764-7 · Cited by 755
To, K. K.-W., Hung, I. F.-N., Ip, J. D., Chu, A. W.-H., Chan, W.-M., Tam, A. R., Fong, C. H.-Y., Yuan, S., Tsoi, H.-W., Ng, A. C.-K., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1275 · Cited by 746
Addetia, A., Crawford, K. H. D., Dingens, A., Zhu, H., Roychoudhury, P., Huang, M.-L., Jerome, K. R., Bloom, J. D., & Greninger, A. L. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.02107-20 · Cited by 525
Flagged first, then by citations
Research works printed but not linked: 2
- Muecksch F, Wise H, Batchelor B, et al. Longitudinal analysis of serology and neutralizing antibody levels in COVID19 convalescents. J Infect Dis 2020 November 3 (Epub ahead of print).33140086
- To KK-W, Hung IF-N, Ip JD, et al. COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing. Clin Infect Dis 2020 August 25 (Epub ahead of print).32840608
Cited by
Sorted by citations
Items 901–913 of 913
Lee, C. C., Segaloff, H. E., Cole, D., Rosenblum, H. G., Morgan, C. N., Somers, T. S., Desamu-Thorpe, R., Foster, M. A., Currie, D. W., Ruff, J. C., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19498051
Additional file 1 of Modelling the impact of hybrid immunity on future COVID-19 epidemic waves
Le, T. P., Abell, I. R., Conway, E. J., Campbell, P. T., Hogan, A. B., Lydeamore, M., McVernon, J., Mueller, I., Walker, C. R., & Baker, C. M. (2024) · Figshare · doi:10.6084/m9.figshare.26707427
Semelka, C., DeWitt, M. E., Blevins, M. W., Holbrook, B. C., Sanders, J. W., & Alexander‐Miller, M. A. (2024) · Figshare · doi:10.6084/m9.figshare.26561866
Violán, C., Torán‐Monserrat, P., Quirant‐Sánchez, B., Lamonja-Vicente, N., Carrasco-Ribelles, L. A., Chacón, C., Domínguez, J. M. M., Ramos‐Roure, F., Dacosta‐Aguayo, R., Palacios-Fernández, C., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20887424
Natarajan, H., Xu, S., Crowley, A. R., Butler, S. E., Weiner, J. A., Bloch, E. M., Littlefield, K., Benner, S. E., Shrestha, R., Ajayi, O., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19185709
Kroidl, I., Winter, S., Rubio‐Acero, R., Bakuli, A., Geldmacher, C., Eser, T. M., Deák, F., Horn, S., Zielke, A., Ahmed, M. I. M., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24077073
Why you should get a COVID-19 vaccine – even if you’ve already had the coronavirus
Grier, J. (2021) · The Conversation · doi:10.64628/aai.ffwxvgkmg
A predictive model for rapid assessment of protective efficacy against emerging SARS-CoV-2 variants
Jin, L., Jia, S., Shao, C., Shen, R., Jin, P., & Li, J. (2026) · Infectious Disease Modelling · doi:10.1016/j.idm.2026.03.003
Wijaya, R. S., Stoddart, J., Adhikari, A., Abayasingam, A., Bartlett, A. W., Rawlinson, W. D., Mina, M., Post, J. J., Hudson, B. J., Gilroy, N., et al. (2026) · Journal of Immunology Research · doi:10.1155/jimr/7429749
Changes in antibody titers over time after infection in Bizen City, Japan
Kadowaki, T., Sasaki, A., Matsumoto, N., Mitsuhashi, T., Hagiya, H., Takao, S., & Yorifuji, T. (2026) · Japanese Journal of Infectious Diseases · doi:10.7883/yoken.jjid.2025.252
COVID-19–Related Healthcare Utilization and Costs in a Large Insured US Population, 2021–2025
Dong, X., Leidner, A. J., Pike, J. J., Cho, B., Wallace, M., & Zhou, F. (2026) · Applied Health Economics and Health Policy · doi:10.1007/s40258-026-01062-2
Kinetics of immunological memory to SARS-CoV-2
Crotty, S., Sette, A., & Weiskopf, D. (2022) · ImmPort · doi:10.21430/m3s4ozjrcn
Crotty, S., Sette, A., & Weiskopf, D. (2022) · ImmPort · doi:10.21430/m31tx0gfhu
Metadata
- Authors
- Lumley, S. F., O’Donnell, D., Stoesser, N. E., Matthews, P. C., Howarth, A., Hatch, S. B., Marsden, B. D., Cox, S., James, T., Warren, F., Peck, L. J., Ritter, T. G., de Toledo, Z., Warren, L., Axten, D., Cornall, R. J., Jones, E. Y., Stuart, D. I., Screaton, G., Ebner, D., Hoosdally, S., Chand, M., Crook, D. W., O’Donnell, A.-M., Conlon, C. P., Pouwels, K. B., Walker, A. S., Peto, T. E. A., Hopkins, S., Walker, T. M., Jeffery, K., & Eyre, D. W.
- Affiliations
- Public Health England (GB)
- From Oxford University Hospitals NHS Foundation Trust (S.F.L., N.E.S., P.C.M., S.C., T.J., F.W., L.W., D.A., A.-M.O., K.J.), Nuffield Department of Medicine (S.F.L., D.O., N.E.S., P.C.M., A.H., S.B.H., B.D.M., R.J.C., E.Y.J., D.I.S., G.S., D.E., S. Hoosdally, D.W.C., C.P.C., A.S.W., T.E.A.P., T.M.W.), the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (N.E.S., P.C.M., S. Hoosdally, D.W.C., A.S.W., T.E.A.P., D.W.E.), the Kennedy Institute of Rheumatology Research (B.D...
- Corresponding author
- Eyre, David W.
- ORCID
- Lumley, Sheila F.
- Stoesser, Nicole E.
- Matthews, Philippa C.
- Hatch, Stephanie B.
- Marsden, Brian D.
- Peck, Liam J.
- Ritter, Thomas G.
- Cornall, Richard J.
- Stuart, David I.
- Screaton, Gavin
- Ebner, Daniel
- Hoosdally, Sarah
- Chand, Meera
- Crook, Derrick W.
- Conlon, Christopher P.
- Pouwels, Koen B.
- Walker, A. Sarah
- Peto, Tim E.A.
- Hopkins, Susan
- Jeffery, Katie
- Eyre, David W.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-11
- Volume
- 384
- Issue
- 6
- Pages
- 533-540
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7781098
- OpenAlex
- W3117382778
- Cited by
- 940
- References
- 29
- Citations by year
- 2026: 7 · 2025: 26 · 2024: 53 · 2023: 103 · 2022: 299 · 2021: 434
- FWCI
- 28.01
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- medRxiv (acceptedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- U.K. Government
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- SARS-CoV-2, COVID-19 reinfection, healthcare workers, anti-spike IgG, seropositivity, seroconversion, asymptomatic infection, symptomatic infection, infection incidence, antibody status
- MeSH terms
- Seroconversion, COVID-19, SARS-CoV-2, Coronavirus Nucleocapsid Proteins, COVID-19 Nucleic Acid Testing, COVID-19 Serological Testing, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Viral, Female, United Kingdom, Health Personnel, Humans, Immunoglobulin G, Longitudinal Studies, Male, Middle Aged, Recurrence, Incidence, Polymerase Chain Reaction, Young Adult, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
